The Administrative Core, led by Dr. Frederick Lang (Director) and Dr. Juan Fueyo (Co-Director), provides critical centralized administrative support to ensure the success of the entire SPORE. The specific objectives of the Administrative Core are to: Oversee and administer all SPORE activities. Oversee all SPORE Projects and Core activities. Oversee the Developmental Research and Career Development Programs. Promote integration and communication between the SPORE, the Brain Cancer Program, and the Cancer Center Support Grant. Ensure compliance with institutional, governmental, and NCI regulations. Communicate and consult with the NCI program officer and other staff to ensure timely preparation and submission of reports, publications, and Important events that affect management of the SPORE. Oversee and administer all fiscal and budgetary activities of the SPORE. Manage and provide quality assurance, including data quality control, in cooperation with the Biostatistics and Bioinformatics Core. Coordinate meetings of the Executive Committee, Internal and External Advisory Boards, monthly investigator meetings, lectures, and symposia. Ensure compliance with and improvement of policies for recruitment of women and minorities. Coordinate with other Brain Cancer SPORE programs and investigators, as well as other organ site SPORE programs, to promote research communication in meetings, distribution of materials, electronic communications, and evaluation of progress reports.
The Administrative Core provides the support and infrastructure for research and financial oversight;clear and open communications among all SPORE investigators, patient advocates, and developmental awardees;and regulatory monitoring to optimize the successful outcome of the translational research in brain cancer.
|Wang, Yugang; Xia, Yan; Lu, Zhimin (2018) Metabolic features of cancer cells. Cancer Commun (Lond) 38:65|
|Noh, Hyangsoon; Zhao, Qingnan; Yan, Jun et al. (2018) Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett 433:176-185|
|Lee, Jong-Ho; Liu, Rui; Li, Jing et al. (2018) EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. Mol Cell 70:197-210.e7|
|Lang, Frederick F; Conrad, Charles; Gomez-Manzano, Candelaria et al. (2018) Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36:1419-1427|
|Wang, Qianghu; Hu, Baoli; Hu, Xin et al. (2018) Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 33:152|
|Dong, Jianwen; Park, Soon Young; Nguyen, Nghi et al. (2018) The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells. Oncotarget 9:10497-10509|
|Thomas, Jonathan G; Parker Kerrigan, Brittany C; Hossain, Anwar et al. (2018) Ionizing radiation augments glioma tropism of mesenchymal stem cells. J Neurosurg 128:287-295|
|Lu, Zhimin; Hunter, Tony (2018) Metabolic Kinases Moonlighting as Protein Kinases. Trends Biochem Sci 43:301-310|
|Jacobs, Daniel I; Liu, Yanhong; Gabrusiewicz, Konrad et al. (2018) Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol 136:33-39|
|Lu, Sean; Wang, Yugang (2018) Nonmetabolic functions of metabolic enzymes in cancer development. Cancer Commun (Lond) 38:63|
Showing the most recent 10 out of 232 publications